BD Extends Longstanding Expertise in Diabetes Management to Benefit Pets

FRANKLIN LAKES, N.J., April 26, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading medical technology company, announced today that it has launched BD Pet Syringes – veterinary insulin syringes for use with U-40 insulins that are administered to dogs and cats with diabetes.

The main treatment to regulate glucose in diabetic pets is the administration of insulin by injection. To address the insulin requirements of pets, BD's Pet Syringe was designed with U-40, a smaller concentration insulin, compared to the standard U-100 insulin available for human medicine.

"BD has been committed to improving the lives of people with diabetes for more than 90 years," said Kenneth Miller, worldwide president of Diabetes Care for BD. "We are delighted to deliver our innovation and quality to pet owners to help ensure that they are giving their pets accurate amounts of insulin, and help their pets with diabetes live healthier lives."

BD Pet Syringes are available in both 0.5mL and 0.3mL sizes to accommodate various levels of insulin dosing. They feature a red scale mark to distinguish the U-40 insulin syringe from the U-100 insulin syringe, which have black scale marks and half-unit scale markings to help ensure more precise dosing. BD Pet Syringes feature a 12.7mm needle length to accommodate a variety of skin thickness and fur density. The 29 gauge needle helps reduce the risk of bending and breaking should the pet move during injection.

U-40 Veterinary Insulin Syringes are currently available through veterinary offices. Visit http://www.bd.com/us/petdiabetes for more information.

About BD

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance cellular studies and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit www.bd.com.

Contact:
Lindsay Roman  
BD Public Relations                                                                           
201.847.4312
[email protected]

SOURCE BD (Becton, Dickinson and Company)